ESR1 and breast cancer: Since a significant sub-set of metastatic ER-positive BC patients harbor ET resistance (due to ESR1 mutations or other cellular adaptations), our findings suggest that such patients may harbor radiation-resistant metastatic sites and may benefit from treatment with a combination of RT + BET inhibitor.